Flow cytometry analysis of DPT cell subpopulations extracted from cultured human liver slices.

<p>Human liver slices (350 µm thick) were obtained from the surgery of uninfected patients and inoculated (MOI = 0.1), or not, with HCVcc of the strain JFH-1 (genotype 2a) produced in the HCV-permissive Huh-7.5 cell line; after 5 days <i>ex vivo</i>, LILs were isolated from the slices and analyzed as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020145#pone-0020145-g001" target="_blank">Figure 1</a>.</p

Average ratios of CD4^highCD8^low cells/CD4^lowCD8^high cells in the blood and liver of each group of patients.

<p>Error bars represent standard deviations. Statistical analysis was performed using a Mann-Whitney test.</p

Proportions of CD4^highCD8^low, CD4^highCD8^high and CD4^lowCD8^high DPT cells in the blood and liver of patients.

<p><b>A,</b> Proportions of each DPT cell subpopulations: CD4^hiCD8^lo (1), CD4^hiCD8^hi (2) and CD4^loCD8^hi (3) in the blood of each patient (1 dot = 1 patient); percentages lower than 0.05 were plotted as 0. <b>B,</b> Same procedure as in (<b>A</b>) with LILs. Horizontal lines represent the values of the median for each DPT subpopulation in each group of patients; the three subpopulations of DPT cells correspond to the quadrants set-up in the lower right panel of <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020145#pone-0020145-g001" target="_blank">Figure 1A</a>, (numbers between brackets).</p

<i>In situ</i> study of LILs by immuno-fluorescence in liver sections of uninfected and HCV-infected patients.

<p>Results obtained with liver biopsies from an uninfected (left panels) and an HCV-infected (right panels) patient. 10-µm serial sections were labeled with CD4 and CD8 antibodies (middle and bottom panels) or isotype controls (top panels). Scale bar: 100 µm. Right Insets: relative fluorescence intensities along the red bars in the left insets plotted on a semi-logarithmic scale (0–100), for the red (CD8) and green (CD4) light channels.</p

HCV and HBV mono-infected patients display distinct patterns of DPT cells.

<p><b>A,</b> Correlation between the proportions of CD4^hiCD8^lo DPT cell subpopulations (1) in blood and liver of HCV mono-infected patients; other subpopulations did not significantly correlate. <b>B,</b> Correlation between the proportions of CD4^loCD8^hi DPT cell subpopulations (3) in blood and liver of HBV mono-infected patients; CD4^hiCD8^hi correlated to the same extent as CD4^loCD8^hi (respectively 2 and 3) in HBV-infected patients (not shown). Each dot represents the proportions in blood and liver for a patient; significance of Pearson's correlation was tested using a t-test. The numbers between brackets correspond to the quadrants set-up in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020145#pone-0020145-g001" target="_blank">Figure 1A</a>, lower right panel.</p

Proportions of DPT cells in the blood and liver of chronically HCV- or HBV-infected, HCV-HIV co-infected and non-infected patients.

<p><b>A,</b> Representative dot plot of PBMCs labeled with the BD Multitest 6-Color TBNK Reagent: CD45⁺CD16⁻CD56⁻ CD19⁻CD3⁺ PBMCs were analyzed for CD4 and CD8 expressions; viability of the CD4⁺CD8⁺ cells was separately assessed with Live/Dead Cell Viability Assay (>95%). <b>B,</b> Proportions of total CD4⁺CD8⁺CD3⁺ (DPT) cells in peripheral blood and liver biopsy for each patient of the different groups. In grey, the experimental points with values above the thresholds (dashed lines) determined in (<b>C</b>), with the corresponding numbers of patients at the top (above threshold/total). <b>C,</b> Determination of the thresholds: 3% in the blood and 10% in the liver.</p

Relationship between socio-demographical, biological and histological variables and SVR among 93 chronic hepatitis C patients treated with combined therapy.

1<p>Multivariate analysis includes GGT, AFP, Fibrosis score and genotype</p><p>OR, odds-ratio; CI, confidence interval, AFP, alpha-foetoprotein; GGT, serum gamma glutamyl transpeptidase</p>2<p>Dose of treatment was considered adequate if patients had received at least 80% of the intended dose for at least 80% of the duration of treatment</p

Female Patient, Aged 56 Years (Patient 2).

<p>Coronal (a) and transaxial (b) localizing image planned along the course of the portal vein (line). Based on these images, a phase-contrast enconding sequence was planned perpendicular to the course of the portal vein (line). c: Portal vein (arrowhead) velocity-encoded phase-contrast image. d: Portal vein (arrow) magnitude image.</p

Venous Flow at base line.

<p>Results are expressed as mean ± SD.</p

Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.

<p>(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.</p